Mitomics Inc. (“Mitomics”) is a molecular diagnostic company engaged in research, development and implementation of medical tests and devices for the early detection of cancers. An application was made by Harald Smart and William Poulter on August 7, 2014 (the “Application”) for an Order pursuant to section 243(1) of the Bankruptcy and Insolvency Act and section 101 of the Courts of Justice Act appointing Dodick Landau Inc. as receiver (in such capacities, the “Receiver”) of all of the assets, undertakings and properties of Mitomics. On August 14, 2014, the Application was granted by the Superior Court of Justice (the “Court”) and the Receiver was appointed (“Appointment Order”). Pursuant to the Appointment Order, a stay of proceedings has been initiated and all proceedings against Mitomics are stayed as of the date of filing of the Appointment Order. On October 8, 2014, the Receiver filed with the Official Receiver a proposal in the name, and on behalf, of Mitomics (the “Proposal”), and DLI was named Proposal Trustee. On October 22, 2014, the Proposal was amended (“Amended Proposal”). On October 27, 2014 and November 6, 2015, the Amended Proposal was approved by the creditors of Mitomics and the Court, respectively. On November 21, 2014 the Receiver completed the sale of all the assets of Mitomics to MDNA Life Sciences Inc. in accordance with the terms of the Amended Proposal.